Colonic Delivery of Nutrients for Sustained and Prolonged Release of Gut Peptides: A Novel Strategy for Appetite Management

Obesity is one of the major global threats to human health and risk factors for cardiometabolic diseases and certain cancers. Glucagon‐like peptide‐1 (GLP‐1) plays a major role in appetite and glucose homeostasis and recently the USFDA approved GLP‐1 agonists for the treatment of obesity and type 2 diabetes. GLP‐1 is secreted from enteroendocrine L‐cells in the distal part of the gastrointestinal (GI) tract in response to nutrient ingestion. Endogenously released GLP‐1 has a very short half‐life of <2 min and most of the nutrients are absorbed before reaching the distal GI tract and colon, which hinders the use of nutritional compounds for appetite regulation. The review article focuses on nutrients that endogenously stimulate GLP‐1 and peptide YY (PYY) secretion via their receptors in order to decrease appetite as preventive action. In addition, various delivery technologies such as pH‐sensitive, mucoadhesive, time‐dependent, and enzyme‐sensitive systems for colonic targeting of nutrients delivery are described. Sustained colonic delivery of nutritional compounds could be one of the most promising approaches to prevent obesity and associated metabolic diseases by, e.g., sustained GLP‐1 release.